Literature DB >> 27428578

Substantially lowered dolutegravir exposure in a treatment-experienced perinatally HIV-1-infected pregnant woman.

Stein Schalkwijk1, Cornelia Feiterna-Sperling, Katharina Weizsäcker, Angela Colbers, Christoph Bührer, Rick Greupink, Frans G M Russel, David Burger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27428578     DOI： 10.1097/QAD.0000000000001123

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  4 in total

1.  Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically-Based Pharmacokinetic Modeling.

Authors:  Jolien J M Freriksen; Stein Schalkwijk; Angela P Colbers; Khaled Abduljalil; Frans G M Russel; David M Burger; Rick Greupink
Journal:  Clin Pharmacol Ther       Date:  2020-01-24       Impact factor: 6.875

2.  Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review.

Authors:  Andrew Hill; Polly Clayden; Claire Thorne; Rachel Christie; Rebecca Zash
Journal:  J Virus Erad       Date:  2018-04-01

Review 3.  Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps.

Authors:  Ruben van der Galiën; Rob Ter Heine; Rick Greupink; Stein J Schalkwijk; Antonius E van Herwaarden; Angela Colbers; David M Burger
Journal:  Clin Pharmacokinet       Date:  2019-03       Impact factor: 6.447

4.  Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?

Authors:  Lee Fairlie; Catriona Waitt; Shahin Lockman; Michelle Moorhouse; Elaine J Abrams; Polly Clayden; Marta Boffito; Saye Khoo; Helen Rees; Amandine Cournil; Willem Francois Venter; Celicia Serenata; Matthew Chersich
Journal:  J Int AIDS Soc       Date:  2019-09       Impact factor: 5.396
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.